Mechanisms of immune checkpoint inhibitor-mediated liver injury
Acta Pharmaceutica Sinica B
; (6): 3727-3739, 2021.
Article
in En
| WPRIM
| ID: wpr-922436
Responsible library:
WPRO
ABSTRACT
The immune checkpoints, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein-1/ligand-1 (PD-1/PD-L1) are vital contributors to immune regulation and tolerance. Recently immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy; however, they come with the cost of immune related adverse events involving multiple organs such as the liver. Due to its constant exposure to foreign antigens, the liver has evolved a high capacity for immune tolerance, therefore, blockade of the immune checkpoints can result in aberrant immune activation affecting the liver in up to 20% of patients depending on the agent(s) used and underlying factors. This type of hepatotoxicity is termed immune mediated liver injury from checkpoint inhibitors (ILICI) and is more common when CTLA4 and PD-1/PD-L1 are used in combination. The underlying mechanisms of this unique type of hepatotoxicity are not fully understood; however, the contribution of CD8
Full text:
1
Index:
WPRIM
Language:
En
Journal:
Acta Pharmaceutica Sinica B
Year:
2021
Type:
Article